Today: 11 June 2026
Citigroup stock ends 2025 lower after $1.2 billion Russia-exit loss disclosure — what investors watch next
1 January 2026
3 mins read

Citigroup stock ends 2025 lower after $1.2 billion Russia-exit loss disclosure — what investors watch next

Citigroup stock ends 2025 lower after $1.2 billion Russia-exit loss disclosure — what investors watch next

NEW YORK, December 31, 2025, 20:50 ET — Market closed

  • Citigroup shares ended down 0.4% at $116.69 in the year’s final session.
  • Citi said it cleared internal approvals to sell its remaining Russia business, a deal expected to lead to a roughly $1.2 billion pre-tax loss in the fourth quarter.
  • Next on the calendar: U.S. markets reopen Jan. 2; Citi reports fourth-quarter results on Jan. 14.

Citigroup shares ended 0.4% lower on Wednesday after the bank disclosed that the planned sale of its remaining Russia business would trigger about $1.2 billion in pre-tax losses.

The move matters heading into mid-January bank earnings because the loss will weigh on Citi’s fourth-quarter headline results at a time investors are focused on whether the lender’s multi-year overhaul is lifting returns and simplifying the balance sheet.

Citi said the loss is largely tied to a currency translation adjustment, an accounting item that reflects currency effects when foreign operations are translated back into dollars. The bank said the transaction would be capital neutral to its key regulatory capital measure, common equity tier 1 (CET1), and that the overall divestment is expected to benefit CET1 mainly through the removal of related risk-weighted assets.

A filing showed Citi expects the loss to be recognized in fourth-quarter 2025 results as a reduction to other revenue through a valuation allowance, and that the currency-translation component related to the unit was about $1.6 billion as of Sept. 30, 2025. Citi also said it expects to classify its remaining Russia business as “held for sale,” an accounting label used when a company plans to dispose of an asset. Citi

The stock finished the year’s final session in step with a broader dip on Wall Street, with the S&P 500 down 0.74% and trading subdued in the holiday week.

Investors have treated the Russia exit as another step in Citi’s pullback from non-core and geopolitically complicated exposures, but they are also watching how frequently one-time items obscure progress in core earnings power and capital returns.

Before the next session, markets will stay shut on New Year’s Day and reopen on Friday, Jan. 2, 2026, after regular U.S. stock-market hours ran on Dec. 31.

In early January, traders will also track U.S. economic releases that can move Treasury yields — a key driver for bank net interest income — including the Employment Situation report for December (scheduled for Jan. 9) and the December Consumer Price Index (scheduled for Jan. 13), according to the Labor Department’s calendar.

For Citi specifically, the next major catalyst is fourth-quarter 2025 results, which the bank has scheduled for release at about 8 a.m. ET on Jan. 14, followed by a webcast and conference call at about 11 a.m. ET.

On the chart, Citi shares are below their 52-week high of $122.84, with the stock’s 50-day moving average around $105.28 — levels technical traders often use to gauge momentum and potential support or resistance.

NEW YORK, December 31, 2025, 20:50 ET — Market closed

  • Citigroup shares ended down 0.4% at $116.69 in the year’s final session.
  • Citi said it cleared internal approvals to sell its remaining Russia business, a deal expected to lead to a roughly $1.2 billion pre-tax loss in the fourth quarter.
  • Next on the calendar: U.S. markets reopen Jan. 2; Citi reports fourth-quarter results on Jan. 14.

Citigroup shares ended 0.4% lower on Wednesday after the bank disclosed that the planned sale of its remaining Russia business would trigger about $1.2 billion in pre-tax losses.

The move matters heading into mid-January bank earnings because the loss will weigh on Citi’s fourth-quarter headline results at a time investors are focused on whether the lender’s multi-year overhaul is lifting returns and simplifying the balance sheet.

Citi said the loss is largely tied to a currency translation adjustment, an accounting item that reflects currency effects when foreign operations are translated back into dollars. The bank said the transaction would be capital neutral to its key regulatory capital measure, common equity tier 1 (CET1), and that the overall divestment is expected to benefit CET1 mainly through the removal of related risk-weighted assets.

A filing showed Citi expects the loss to be recognized in fourth-quarter 2025 results as a reduction to other revenue through a valuation allowance, and that the currency-translation component related to the unit was about $1.6 billion as of Sept. 30, 2025. Citi also said it expects to classify its remaining Russia business as “held for sale,” an accounting label used when a company plans to dispose of an asset. Citi

The stock finished the year’s final session in step with a broader dip on Wall Street, with the S&P 500 down 0.74% and trading subdued in the holiday week.

Investors have treated the Russia exit as another step in Citi’s pullback from non-core and geopolitically complicated exposures, but they are also watching how frequently one-time items obscure progress in core earnings power and capital returns.

Before the next session, markets will stay shut on New Year’s Day and reopen on Friday, Jan. 2, 2026, after regular U.S. stock-market hours ran on Dec. 31.

In early January, traders will also track U.S. economic releases that can move Treasury yields — a key driver for bank net interest income — including the Employment Situation report for December (scheduled for Jan. 9) and the December Consumer Price Index (scheduled for Jan. 13), according to the Labor Department’s calendar.

For Citi specifically, the next major catalyst is fourth-quarter 2025 results, which the bank has scheduled for release at about 8 a.m. ET on Jan. 14, followed by a webcast and conference call at about 11 a.m. ET.

On the chart, Citi shares are below their 52-week high of $122.84, with the stock’s 50-day moving average around $105.28 — levels technical traders often use to gauge momentum and potential support or resistance.

Stock Market Today

  • How to Invest Indirectly in SpaceX Before IPO Through ETFs
    June 11, 2026, 10:46 AM EDT. Investors can gain indirect exposure to SpaceX ahead of its IPO via ETFs like ERShares Private-Public Crossover ETF (XOVR) and AGIX. These funds use special purpose vehicles (SPVs)-legal entities holding SpaceX shares-to navigate SEC rules allowing up to 15% allocation in illiquid private companies. XOVR holds about 13.2% exposure to SpaceX through SPVs, while AGIX combines SPV investments with a small direct stake. Investors should note these ETFs are thematic portfolios with broad tech focuses and relatively high expense ratios. Direct public investment remains available only after SpaceX's Nasdaq debut at ticker SPCX on June 12, priced around $135, targeting a $1.75-$2 trillion valuation.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop